Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of Enpatoran (M5049) in Healthy Participants
NCT03676322Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of enpatoran in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) (5 arms), sponsored by Merck KGaA. Primary endpoints: Treatment-emergent Adverse Events, Clinically Significant Changes in Vital Signs, Laboratory Parameters and ECG Findings and 8 more. Started Sep 2018; status: completed.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT03676322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03676322.